Lilly, DexCom, Glooko, myDiabby Healthcare and Roche will provide platforms for diabetes management. Photo credit: Diabetesmagazijn.nl on Unsplash.
Through this partnership, the companies – DexCom, Glooko, myDiabby Healthcare and Roche – will provide diabetes management platforms that work well with Lilly’s Tempo Pen and Tempo Smart Button for treating diabetes.
The Tempo Pen is a version of the company’s disposable pre-filled insulin pen that is approved in various markets around the world. The Tempo Smart Button attached to this pen has yet to be CE marked.
The Tempo Smart Button is used with Dexcom, Glooko, myDiabby Healthcare and Roches software and / or medical devices. A combination of pen and mySugr app from Roche is intended to enable personalized data and actionable insights.
Marie Schiller, vice president of product development at Eli Lilly Connected Care and Insuline, said, “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
“By integrating data from the connected insulin pen solutions into widely used compatible software, including potential future collaborations, we aim to improve decision-making for people with diabetes and their healthcare providers through accurate, real-time data collection.”
Lilly hopes these solutions can help remove psychological barriers such as the fear of hypoglycemia that could negatively affect diabetes management.
Studies have shown that using smart insulin devices with digital health tools improves outcomes for diabetic patients, said Russ Johannesson, CEO of Glooko.
Lilly plans to receive the CE mark for the Tempo Smart Button later this year. Upon receipt of this approval, the company will commercialize the Tempo Pen and Tempo Smart Button in various global markets.
Related companies
Proportion-air
Customized electropneumatic control for medical applications
Related companies
Proportion-air
Customized electropneumatic control for medical applications
August 28, 2020
